Authors
Latest:
Relapsed/Refractory CLL: Practical Advice and Future Directions in CareA key opinion leader on relapsed/refractory chronic lymphocytic leukemia provides practical advice on patient management and looks toward future evolutions in the treatment landscape.
Latest:
Remote Monitoring Improves Management of Symptoms in Patients With Lung Cancer After SurgeryBrett Simon, MD, PhD, discusses an ongoing program at his institution that aims to improve symptoms and outcomes for patients with lung cancer who have undergone surgery.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
Future Directions and Unmet Needs in T-ALLBijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
Germline Testing Outside the Guidelines: Can it Address Health Disparities?The completion of the Human Genome project has ushered in a new era in our understanding of cancer.
Latest:
Excitement Shown With CDK4/6 Inhibitors and More in Breast Cancer ResearchSeth Wander, MD, PhD, discusses what research and topics excite him when looking to further evaluate future treatments for patients with breast cancer.
Latest:
Pandemic Leads to Delays in Crucial Early Cancer Screening TestsClayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.
Latest:
Important Safety Data Evaluated in Meta-Analysis of MyelofibrosisJan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Latest:
Using Comprehensive Genomic Profiling to Identify Rare Subsets of Merkel Cell CarcinomaRyan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Latest:
EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung CancerIn this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.
Latest:
Key Takeaways on Zanubrutinib DataFollowing a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.
Latest:
Integrating Physician Opinions Into DLBCL Treatment SelectionPatrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma
Latest:
T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup AnalysisFam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
Latest:
About the C-800 Trial of Botensilimab/Balstilimab in Ovarian CancerBruno Bockorny, MD, discusses the phase 1 C-800 trial of botensilimab plus bastilimab, specifically for patients in the C-800-01 cohort with recurrent platinum refractory/resistant ovarian cancer.
Latest:
Leukemia Awareness Month: Changing the Future of AML through Precision MedicineGwen Nichols, MD, reviews the evolving landscape of acute myeloid leukemia for Leukemia Awareness Month.
Latest:
An Update on Current and Emergent Therapies for Essential ThrombocytosisThe therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Latest:
Handling GI Toxicities While Using Selinexor Triplet Therapy in RRMMAdam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.
Latest:
Imetelstat and Canakinumab in Lower-Risk MDSDrs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.
Latest:
Dysphagia-Optimized IMRT Shows Significance in Head and Neck CancerChristopher Nutting, MD, discusses the results of a randomized phase 3 trial using dysphagia-optimized intensity modulated radiotherapy versus standard IMRT in patients with head and neck cancer.
Latest:
Role of Ruxolitinib in GVHD TreatmentDrs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.
Latest:
Steroid-Refractory cGvHD: Emerging Treatment OptionsThis segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
Latest:
Tumor-Infiltrating Lymphocytes: Rationale for Use in the Treatment of Solid Tumors and Potential Benefits and DrawbacksIn the second interview of this series, Ben Creelan, MD, Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Latest:
The Future of Treating Small Cell Lung CancerKartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.
Latest:
Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.
Latest:
Findings of the IMMUTACE Trial in Hepatocellular CarcinomaArndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Latest:
Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in MyelomaMehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.
